Patent · US Active

Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

US11634482B2 · kind B2 · utility

0Cited by

5References

15Claims

0Family size

Assignee

Julius-Maximilians-Universitat Wurzburg · DE

Inventors

Jörg WISCHHUSEN · Würzburg, DE
Markus Junker · Würzburg, DE
Tina SCHÄFER · Würzburg, DE
Dirk PÜHRINGER · Rimpar, DE

Key dates

Filing date	Feb 19, 2020
Grant date	Apr 25, 2023
Priority date	—
Expiry date	Jun 5, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/63
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric anti-bodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti-bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.